Dechra Pharmaceuticals PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DCHPF research report →
About the company
Dechra Pharmaceuticals PLC specializes in the entire lifecycle of veterinary products, from development and manufacturing to regulatory approval, marketing, and sales, primarily serving veterinarians. The company's operations are structured across three main divisions: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. Their extensive product portfolio addresses a diverse array of animal health needs.
- CEO
- Isidro A. Consunji
- IPO
- 2016
- Employees
- 2,457
- HQ
- Northwich, GB
Price Chart
- Market Cap
- $5.34B
- P/E
- -161.08
- P/S
- 5.78
- P/B
- 5.81
- EV/EBITDA
- 55.75
- Div Yield
- 0.32%
- Gross Margin
- 55.98%
- Op Margin
- 0.83%
- Net Margin
- -3.66%
- ROE
- -3.92%
- ROIC
- 0.35%
- Revenue
- $761.50M · 11.69%
- Net Income
- $-27,900,000 · -147.94%
- EPS
- $-0.24 · -144.44%
- Op Income
- $6.30M
- FCF YoY
- -26.49%
- 52W High
- $47.40
- 52W Low
- $30.00
- 50D MA
- $47.05
- 200D MA
- $40.79
- Beta
- 0.51
- Avg Volume
- 92
Get TickerSpark's AI analysis on DCHPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DCHPF coverage
Recent articles, reports, and earnings notes.
No research on DCHPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DCHPF report →Similar companies
Peers in the same neighborhood.